Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data

Eur J Cancer. 2021 Oct:156 Suppl 1:S18. doi: 10.1016/S0959-8049(21)00659-6.
No abstract available

Keywords: Sézary syndrome; cutaneous T-cell lymphoma; mycosis fungoides; overall survival; real-world evidence.